UBS Group’s Acura Pharmaceuticals ACUR Stock Holding History

UBS Group’s Portfolio ACUR Stock Details ACUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,000	Closed	-$5K	–	8887
2015 Q2	$5K	Sell	1,000 -1,680	-63%	-$6.98K	﹤0.01%	7915
2015 Q1	$11K	Hold	2,680	–	–	﹤0.01%	7603
2014 Q4	$6K	Buy	+2,680	New	+$7.41K	﹤0.01%	8901

Other funds holding ACUR

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

UBS Group's ACUR Position: Q2 2016 in Review

UBS Group sold out of Acura Pharmaceuticals (ACUR) in Q2 2016, closing a stake of 31 shares.

UBS Group first reported a position in ACUR in Q4 2014 and held it in 4 quarters. The position peaked at $5K in Q2 2015. 22 funds tracked by Wall St. Rank hold ACUR as of Q2 2016.

UBS Group reported no remaining Acura Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
UBS Group sold 31 Acura Pharmaceuticals shares in Q2 2016.
UBS Group first reported a position in Acura Pharmaceuticals in Q4 2014 and held it in 4 quarters.
UBS Group's Acura Pharmaceuticals position peaked at $5K in Q2 2015.
22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q2 2016.

Based on UBS Group's 13F filing for Q2 2016, filed 12 Aug 2016.